KIR3DL1 and acute myeloid leukemia: We investigated the potential of donor KIR genotype information to predict the risk of relapse after HLA-compatible unrelated allogeneic HCT in a large cohort of patients with secondary acute myeloid leukemia (sAML) or a myelodysplastic syndrome (MDS).